Hospira Reports First-Quarter 20...( -- Affirms Sales Project...),Health

-- Affirms Sales Projection and Narrows Earnings Guidance to Upper End of Range for 2009 --

LAKE FOREST, Ill., April 28 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a leading global specialty pharmaceutical and medication delivery company, today reported results for the first quarter ended March 31, 2009. Net sales for the quarter were $860 million, and adjusted* diluted earnings per share were $0.60. (Adjusted* measures exclude certain specified items as described later in this press release and the attached schedules.)

"Hospira delivered on its commitments in the first quarter, generating solid sales and earnings growth in a period marked by continued economic uncertainty," said Christopher B. Begley, chairman and chief executive officer. "Looking forward, we believe the results of our strategic investments and our focus on execution position us well to deliver our financial commitments for 2009. In addition, we are driving operational excellence through our optimization initiatives under Project Fuel, which will create long-term, sustainable growth and increased shareholder value."

First-Quarter 2009 Results

The following table highlights selected financial results for the first quarter of 2009 compared to the same period in 2008:

    In $ millions,              GAAP                     Adjusted*
     except per          Three Months Ended         Three Months Ended
     share amounts            March 31,                  March 31,
                          ----------------     %     ----------------     %
                           2009      2008   Change    2009      2008   Change
                          ------    ------  ------   ------    ------  ------
    Net Sales             $859.7    $888.7   (3.3)%    n/a       n/a     n/a

'/>"/>
SOURCE  Hospira, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
Related medicine news :

1. Hospira to Host Conference Call for First-Quarter 2009 Results
2. Hospira to Present at Cowen and Companys 29th Annual Health Care Conference March 17
3. Hospira Expands Board of Directors
4. Hospira Reports Fourth-Quarter and Full-Year 2008 Results
5. Hospiras Precedex(R) Phase IV Study Published in the Journal of the American Medical Association
6. Hospira to Host Conference Call for Fourth-Quarter 2008 Results and 2009 Projections
7. Hospira to Present at J.P. Morgans 27th Annual Healthcare Conference January 14
8. Hospira Names Ken Meyers to Lead Human Resources
9. Hospira Reports Third-Quarter 2008 Results
10. Hospira to Present at the 2008 Annual Credit Suisse Health Care Conference on November 12
11. FDA Approves New Indication for Hospiras Precedex (Dexmedetomidine HCL) Injection